UNCY (STOCKS)
Unicycive Therapeutics, Inc. Common Stock
$6.620000
-0.010000 (-0.15%)
Prev close: $6.630000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Shalabh Gupta
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $167.07M
- Employees
- 22
- P/E (TTM)
- -3.27
- P/B (TTM)
- 4.86
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
10
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.82 | $-0.48 | -0.3362 | -69.64% |
|
Sep 2025 (Q3)
|
$-0.33 | $-0.57 | +0.2378 | +41.88% |
|
Jun 2025 (Q2)
|
$-0.52 | $-0.75 | +0.2348 | +31.11% |
|
Mar 2025 (Q1)
|
$-0.50 | $-1.16 | +0.6560 | +56.75% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $2.96M |
| Operating Expenses | $29.52M |
| Research and Development | $9.12M |
| Other Operating Expenses | $20.40M |
| Operating Income/Loss | -$29.52M |
| Income/Loss From Continuing Operations After Tax | -$26.56M |
| Income/Loss From Continuing Operations Before Tax | -$26.56M |
| Net Income/Loss | -$26.56M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$26.56M |
| Net Income/Loss Available To Common Stockholders, Basic | -$26.56M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.67 |
| Diluted Earnings Per Share | -$1.67 |
| Basic Average Shares | 15,886,876 |
| Diluted Average Shares | 15,886,876 |
| Assets | $49.14M |
| Current Assets | $48.96M |
| Noncurrent Assets | $174.00K |
| Fixed Assets | $66.00K |
| Other Non-current Assets | $108.00K |
| Liabilities | $18.94M |
| Current Liabilities | $18.94M |
| Accounts Payable | $383.00K |
| Other Current Liabilities | $18.56M |
| Noncurrent Liabilities | $0.00 |
| Equity | $30.20M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $30.20M |
| Liabilities And Equity | $49.14M |
| Net Cash Flow From Operating Activities | -$31.32M |
| Net Cash Flow From Operating Activities, Continuing | -$31.32M |
| Net Cash Flow From Investing Activities | -$12.10M |
| Net Cash Flow From Investing Activities, Continuing | -$12.10M |
| Net Cash Flow From Financing Activities | $46.47M |
| Net Cash Flow From Financing Activities, Continuing | $46.47M |
| Net Cash Flow | $3.06M |
| Net Cash Flow, Continuing | $3.06M |
| Comprehensive Income/Loss | -$26.56M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$26.56M |
| Other Comprehensive Income/Loss | -$26.56M |